Methods of treating disorders with group I mGluR antagonists
US6890931B2 · kind B2 · utility
8Cited by
0References
24Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 2, 2002 |
| Grant date | May 10, 2005 |
| Priority date | — |
| Expiry date | Apr 2, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and uses of mGluR5 antagonists for the treatment and prevention of neurological disorders, such as Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome, are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.